Publications by authors named "Y Rosenberg"
Importance: Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19.
Objective: To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia.
Design, Setting, And Participants: This multicenter, phase 3, placebo-controlled, double-blinded randomized clinical trial was conducted at 41 US sites and 21 international sites between November 17, 2021, and September 27, 2023; the last follow-up visit was December 31, 2023.
Article Synopsis
- The review emphasizes the slow adoption of evidence-based treatments after cardiovascular trials, necessitating early focus on implementation during treatment development and testing.
- It discusses the principles of implementation science, common obstacles, and strategies to promote better integration of these practices into clinical trials.
- The authors suggest various methods to improve early implementation, such as involving diverse stakeholders, modifying eligibility criteria, aligning trials with healthcare systems, and conducting economic analyses, supported by case examples for practical guidance.
The Accelerating COVID-19 Therapeutic Interventions and Vaccines Therapeutic-Clinical Working Group members gathered critical recommendations in follow-up to lessons learned manuscripts released earlier in the COVID-19 pandemic. Lessons around agent prioritization, preclinical therapeutics testing, master protocol design and implementation, drug manufacturing and supply, data sharing, and public-private partnership value are shared to inform responses to future pandemics.
View Article and Find Full Text PDFArticle Synopsis
- CYP2C19 loss of function carriers face a higher risk of ischemic events when treated with clopidogrel during PCI.
- In the TAILOR-PCI study, patients were randomized to receive either clopidogrel or a genotype-guided therapy where LOF carriers were prescribed ticagrelor.
- Although direct medical costs were similar between the two groups, total costs were higher for the GG group mainly due to the more expensive ticagrelor medication.